The Survivor: Termeer focused on resolving Genzyme woes

Now that Carl Icahn's incipient proxy fight has been settled, Genzyme CEO Henri Termeer says that he has no intention of selling the company. And he insists that the company is right where it was ahead of the Icahn showdown, focused on resolving its manufacturing woes and reviving flagging sales. With the scrap with Icahn over "we can get away from that conflict and start to run the company again, moving forward with the very, very exciting developments we have ahead of us," Termeer tells Bloomberg. The CEO adds he'll be ready to step down next year. Genzyme also said that it plans to sell $1 billion in notes. Story | Report

Suggested Articles

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.